UKhetho oluNcinci lweCell Lung Cancer 2026: I-ADC entsha kunye ne-Immunotherapy Breakthroughs 

Iinketho zonyango zomhlaza wemiphunga omncinci weseli ngo-2026 ziye zavela ngokuphawulekayo, ukusuka kwiirejimeni ze-chemotherapy-kuphela ukuya kwiintlanganisela eziphambili ezibandakanya i-immunotherapy, i-antibody-drug conjugates (ADCs), kunye ne-T-cell engagers ekujoliswe kuyo. Imigangatho yangoku ibandakanya iplatinam-based chemotherapy edityaniswe nePD-L1 inhibitors yokhathalelo lokuqala, ngelixa impumelelo emitsha efana neDLL3-targeted therapies kunye ne-anti-antibody ADCs zichaza ngokutsha iziphumo zokusinda kuzo zombini inqanaba elilinganiselweyo kunye nesifo esibanzi.

Ukuqonda iMeko yangoku yoKhetho loNyango loMhlaza weMiphuphu yeSeli encinci

Umhlaza wemiphunga omncinci weseli (SCLC) uhlala ulolona hlobo lunoburhalarhume olubonakaliswa kukukhula okukhawulezayo kunye ne-metastasis yokuqala. Ngokwembali, iinketho zonyango umhlaza wemiphunga encinci zazilinganiselwe kwi-chemotherapy ye-platinum-etoposide, eyabonelela ngeereyithi zokuphendula eziphezulu zokuqala kodwa ukusinda kwexesha elide. Ukusinda kwe-median jikelele kwi-SCLC yenqanaba elibanzi (ES-SCLC) kunqabile ukuba kudlule unyaka omnye.

Nangona kunjalo, indawo yonyango iye yatshintsha i-paradigm. Udibaniso lwe-immune checkpoint inhibitors kwiiprothokholi zodidi lokuqala lube ngumgangatho omtsha wehlabathi. Ngaphaya koko, u-2026 uphawula unyaka obalulekileyo apho iindlela zenoveli, ezibandakanya ii-bispecific T-cell engagers kunye nesizukulwana esilandelayo see-ADCs, zisuka kumanqanaba ovavanyo ukuya kwinyani yeklinikhi. Olu phuculo lujongene nesidingo esibalulekileyo sonyango olusebenzayo lodidi lwesibini nolwesithathu, ummandla othe wahlala amashumi eminyaka.

Ukuhlelwa kwe-SCLC kwi-Limited-Stage (LS-SCLC) kunye ne-Extensive-Stage (ES-SCLC) iyaqhubeka nokumisela isicwangciso sokuqala sonyango. I-LS-SCLC inokunyangeka kunye ne-chemoradiotherapy elandelwa yi-consolidation immunotherapy. Ngokwahlukileyo, i-ES-SCLC ilawulwa njengemeko engapheliyo, igxile ekwandiseni ukusinda kunye nokugcina umgangatho wobomi ngokusebenzisa unyango lwenkqubo. Ukuqonda le yantlukwano kubalulekile kwizigulana kunye nabanonopheli abajonga uluhlu oluntsonkothileyo olukhoyo iinketho zonyango umhlaza wemiphunga encinci.

Indima yeMolekyuli yokuChwetheza kancinci kuNyango lwangoku

Uphando olutshanje luye lwagxininisa i-heterogeneity ye-SCLC, ekhokelela ekuchongeni i-molecular subtypes esekelwe ekubonakalisweni kwezinto eziphambili zokubhala ezifana ne-ASCL1, NEUROD1, POU2F3, kunye ne-YAP1. Le stratification ayisenamfundo nje; iyaqala ukuba nefuthe kuyilo lolingo lwezonyango kunye neendlela zonyango zomntu. Ngokomzekelo, ezinye ii-subtypes zingaphendula ngcono kwii-immunotherapies ezithile okanye kwii-arhente ezijoliswe kuzo ezifana ne-DLL3 inhibitors.

Ngelixa uhlolo jikelele kwezi subtypes ingekabikho ngokwesiqhelo kuzo zonke iiklinikhi, ukuqaphela oku kwantlukwano kwebhayoloji kunceda ekucaciseni ukuba kutheni ezinye izigulana ziphendula ngokugqwesileyo kunyango logonyo ngelixa ezinye zingaphenduli. Njengoko sihamba ngo-2026, okulindelekileyo kukuba iprofayili yeemolekyuli iya kuba yinxalenye esemgangathweni yokuqhutywa komsebenzi wokuxilonga, iphucula ngakumbi ukhetho lwe. iinketho zonyango umhlaza wemiphunga encinci.

Imigangatho yokuQala yoMmandla: I-Immunotherapy Combinations

Ilitye lembombo kunyango lwangoku lodidi lokuqala lomhlaza wemiphunga omncinci wenqanaba elibanzi yindibaniselwano yechemotherapy esekwe kwiplatinam kunye ne-immune checkpoint inhibitor. Le ndlela ibonise inzuzo yokusinda ehambelanayo kwiimvavanyo ezininzi zeSigaba sesi-III esikhulu, ukuseka umgangatho omtsha wokunyamekela.

Umatshini ubandakanya ukusebenzisa ichemotherapy ukukhuthaza ukufa kweseli ye-immunogenic, ngokufanelekileyo "i-priming" i-tumor microenvironment. I-immunotherapy eyongeziweyo, ngokuqhelekileyo i-PD-L1 okanye i-PD-1 inhibitor, ikhusela ukungasebenzi kweeseli ze-T, ukuvumela amajoni omzimba ukuba agcine uhlaselo kwiiseli zomhlaza. Le synergy iguqule i-prognosis yezigulane ezininzi.

• Atezolizumab: Ngokusekwe kulingo lwe-IMpower133, i-atezolizumab idityaniswe ne-carboplatin kunye ne-etoposide yayiyirejimeni yokuqala yokubonisa inzuzo ebalulekileyo yokusinda. Idatha yokulandelela ixesha elide evezwe ngo-2026 iqinisekisa ukusinda kwemisila, kunye ne-subset yezigulane eziphila ngaphaya kweminyaka emihlanu.
• Durvalumab: Ulingo lwe-CASPIAN luseke i-durvalumab kunye neplatinam-etoposide njengenye inketho eyomeleleyo. Uhlaziyo lwakutsha nje luqaqambisa iprofayile yokhuseleko olululo kunye nokuguquguquka kokucwangcisa, oko kuyenza ibe lukhetho olukhethwayo kwiinkqubo ezininzi zokhathalelo lwempilo.
• Serplulimab: Idatha ekhulayo ibonisa ukuba i-serplulimab, inoveli ye-PD-1 inhibitor, inika ukusebenza okunamandla. Uphononongo oluthiwe thaca kwiinkomfa ezinkulu ze-oncology ngo-2026 lubonisa iziphumo ezithembisayo xa zisetyenziswa ngokudityaniswa nechemotherapy, ngakumbi kwidemographics yezigulane ezithile.
• Adebrelimab: Olu tshintsho lwasekhaya lubonise iziphumo eziphawulekayo kwizifundo ezinkulu. Uhlaziyo lwexesha elide lweCAPSTONE-1 lubonisa uphuculo olubonakalayo kubomi obuphakathi, ukuqinisa ixabiso lee-agent ezahlukeneyo ze-immunotherapy kwi-arsenal yonyango.

UNyango oluManyeneyo lweSifo esinenqanaba elilinganiselweyo

Kwizigulane ezinesigaba esilinganiselweyo, injongo yonyango yonyango. Umgangatho wokhathalelo ubandakanya i-chemoradiotherapy (cCRT). Impumelelo enkulu kule minyaka yakutsha nje kukwamkelwa konyango lokuqinisa amajoni omzimba olulandela i-cCRT.

Ulingo lwe-ADRIATIC lube ngumtshintshi-mdlalo kwesi seto. Kubonise ukuba ukulawula i-durvalumab njengonyango oludityanisiweyo emva kwe-cCRT ephumelelayo kwandisa kakhulu ukusinda okungenankqubela kunye nokusinda ngokubanzi. Oku kufunyanisiweyo kuye kwakhokelela ekuvunyweni kolawulo kunye nohlaziyo lwesikhokelo, ukwenza ukuhlanganiswa kwe-immunotherapy kuqwalaselo olusinyanzelo lwezigulane ezifanelekileyo ze-LS-SCLC.

Ukongeza, uphando kwiishedyuli ze-radiotherapy ze-hypofractionated ezidityaniswe ne-immunotherapy ziyaqhubeka. Iziphumo zakwangoko zicebisa ukuba ukuguqula iipatheni zemitha yokudosa kunokonyusa ukusabela komzimba, kunokuphucula iziphumo ngakumbi. Ezi zicwangciso eziphuhlayo zimele i-cut cut of iinketho zonyango umhlaza wemiphunga encinci kwizifo zasekhaya.

Ukunyuka kwe-Antibody-Drug Conjugates (ADCs)

I-Antibody-Drug Conjugates (ADCs) imele udidi lwenguqu iinketho zonyango umhlaza wemiphunga encinci. Ngokungafaniyo nechemotherapy yesiko, echaphazela zonke iiseli ezahlula-hlula ngokukhawuleza, ii-ADCs zisebenza “njengemijukujelwa ekhokelwayo.” Ziquka i-antibody ejolise kwiprotheyini ethile kumphezulu weseli yomhlaza, edityaniswe kumthwalo onamandla we-cytotoxic. Nje ukuba i-antibody ibophelele ekujoliswe kuyo, i-complex ifakwa ngaphakathi, kwaye umthwalo wentlawulo ukhutshwa ngokuthe ngqo ngaphakathi kwiseli yethumba, ukunciphisa umonakalo kwizicubu eziphilileyo.

Ngo-2026, ii-ADCs zifumana ukutsaleka hayi nje njengonyango lodidi lwesibini kodwa ngokudityaniswa nonyango lwamajoni omzimba kunyango lodidi lokuqala. Le ndlela imbini iphakamisa ukuchaneka kwe-ADC kunye namandla enkqubo yokuvuselela umzimba.

I-B7-H3 ii-ADC ezijoliswe kuzo: I-IFinatamab Deruxtecan

Olunye uphuhliso olunomdla kakhulu kukuvela kwe-B7-H3 ejoliswe kwi-ADCs, njenge-finatamab deruxtecan (I-DXd). I-B7-H3 yiprotheyini echazwe kakhulu kwiiseli ze-SCLC kodwa zilinganiselwe kwizicubu eziqhelekileyo, okwenza kube yinto ekujoliswe kuyo efanelekileyo.

Idatha yeklinikhi enikezelwe kutshanje ibonisa isithembiso esingaqhelekanga. Kwizigulane ezine-SCLC ezibanzi eziye zaqhubela phambili emva konyango lwangaphambili, i-I-DXd ibonise izinga lokuphendula lenjongo elidlula i-50% kunye nezinga lokulawula isifo ngaphezu kwe-90%. Mhlawumbi ngokubaluleke kakhulu, le arhente ibonise ukukwazi ukuwela umqobo wegazi-ubuchopho.

I-Metastases yobuchopho yinto eqhelekileyo kunye neyonakalisayo ye-SCLC. Unyango lwesintu ludla ngokusilela ukungena kumbindi wemithambo-luvo ngempumelelo. Ukukwazi kwe-I-DXd ukucutha amathumba e-intracranial kunika indlela yokuphila kwizigulana ebezinokhetho olumbalwa ngaphambili. Ulingo oluqhubekayo lweSigaba sesi-III luthelekisa le arhente ngokuchasene nekhemotherapy eqhelekileyo, kunye neziphumo ezilindelekileyo ezinokuchaza kwakhona umgangatho wodidi lwesibini wokhathalelo.

Ii-ADC eziThage kabini: Iza-bren (BL-B01D1)

Omnye umda kukuphuhliswa kwee-ADCs ezimbini. Iza-bren (BL-B01D1) yi-EGFR × HER3 ejoliswe kabini kwi-ADC. Ngelixa i-EGFR kunye ne-HER3 zixhaphake ngokunxulunyaniswa nomhlaza wemiphunga weseli ongeyonxalenye encinci, intetho yabo kwi-SCLC kunye nendlela eyodwa yeli chiza ivelise iziphumo ezimangalisayo.

Izifundo zeSigaba sesi-II zakutsha nje ezidibanisa i-iza-bren kunye ne-serplulimab zichaze iimetriki ezingazange zibonwe ngaphambili. Idatha ibonisa izinga lokusinda lonyaka omnye lilonke lisondela kuma-86%, inani elisebenza kakhulu ngaphezu kweebenchmarks zembali kwisigaba esibanzi sesifo. Umatshini ubonakala ungabandakanyi nje ukubulawa kweeseli ngokuthe ngqo kodwa kunye nokuguqulwa kwamathumba "abandayo" (angasebenzi ngomzimba) abe ngamathumba "ashushu", ngaloo ndlela ephucula ukusebenza konyango lokugonyela kwangaxeshanye.

Esi siphumo se-synergistic sigxininisa intsingiselo ephambili ngo-2026: inyathelo eliya kunyango olunengqiqo. Ngokudibanisa i-ADC eyenza i-immunogenic cell death kunye ne-checkpoint inhibitor ekhupha iibhuleki kwi-immune system, oogqirha bafezekisa iimpendulo ezinzulu kunye nezizinzileyo. Olu tshintsho lwandisa i-horizon ye-viable iinketho zonyango umhlaza wemiphunga encinci.

Ujoliso lwe-DLL3: Ixesha elitsha le-Precision Medicine

I-Delta-like ligand 3 (DLL3) yiprotheyini engaphezulu efumaneka kuninzi lweeseli zomhlaza wemiphunga yeseli encinci kodwa ingekho kwizicubu eziqhelekileyo zabantu abadala. Oku kuyenza ibe yinjongo egqibeleleyo yeyeza elichanekileyo. Kangangeminyaka, ukujolisa kwi-DLL3 kubonakala kunzima, kodwa u-2026 ubone ukuvuthwa kweendlela ezimbini ezahlukeneyo: i-Bispecific T-cell Engagers (BiTEs) kunye neRadioligand Therapies.

Tarlatamab: I-Bispecific T-cell Engager

I-Tarlatamab yi-bispecific T-cell engageer edibanisa ngokwasemzimbeni iiseli ze-T zesigulana kunye neeseli zomhlaza ezibonisa i-DLL3. Ngokuvala lo msantsa, inyanzela amajoni omzimba ukuba ahlasele ithumba nokuba iiseli ze-T ziyawubona ngokwemvelo umhlaza.

Ukuvunywa okukhawulezileyo kunye neenkqubo zofikelelo ezandisiweyo zenze ukuba i-tarlatamab ifumaneke kwizigulana ezine-SCLC ebuyela umva okanye i-refractory. Ulingo lwezonyango lubonise amazinga okuphendula okunenjongo phakathi kwe-40% kunye ne-55% kubantu abanyangwa kakhulu ngaphambili, inani labantu elibona amazinga okuphendula angaphantsi kwe-10% nge-chemotherapy eqhelekileyo.

Nangona kunjalo, ukusetyenziswa kwe-tarlatamab kufuna ukulawulwa ngononophelo. Ukusebenza okunamandla kweeseli ze-T kunokukhokelela kwi-Cytokine Release Syndrome (CRS), impendulo yokuvuvukala kwenkqubo. Ukongezelela, idatha yelizwe langempela igxininise imingcipheko ethile ye-pneumonitis kunye ne-nephritis. Oogqirha ngoku basebenzisa iindlela zokudosa okonyusa kunye nemigaqo yokuhlola engqongqo ukunciphisa le mingcipheko, beqinisekisa ukuba iingenelo ezinzulu zolu nyango zinokufezekiswa ngokukhuselekileyo.

Radioligand Therapy Targeting DLL3

Ngaphaya kokubandakanyeka kweselula, i-DLL3 ikwajoliswa kunyango lwe-radioligand. Le ndlela ibandakanya ukuncamathisela i-isotope yeradioactive kwi-antibody okanye i-peptide ebophelela kwi-DLL3. Imitha ihanjiswa ngqo kwindawo yethumba, igcina amalungu asempilweni ayingqongileyo.

Izilingo zesigaba sokuqala zibonisa ukuba le ndlela inokuthi isebenze ngokukodwa kwizigulane ezinezifo ezixhaphakileyo ze-metastatic, kubandakanywa nezo zinenxaxheba yamathambo kunye nengqondo. Ukukwazi ukuhambisa idosi ephezulu yokusasazeka kwemitha ngokwenkqubo ngaphandle kokutyhefa kwemitha yemitha yangaphandle kuyinzuzo enyanzelekileyo. Ngelixa kusaphandwa kakhulu ngo-2026, oku kubonisa ikamva Ukhetho lonyango lomhlaza wemiphunga yeseli encinci ezinokuthi kungekudala zingene kuqheliselo oluqhelekileyo.

Uhlalutyo oluthelekisayo lwezonyango ezisakhulayo

Ngokungena kwamachiza amatsha, ukukhetha indlela efanelekileyo kunokuba nzima. Le theyibhile ilandelayo ithelekisa isitshixo esivelayo iinketho zonyango umhlaza wemiphunga encinci kuxoxwe, kuqaqambisa iindlela zabo, imeko yangoku, kunye namatyala afanelekileyo okusetyenziswa.

Olu thelekiso lugxininisa ukwahlukana kwenkangeleko yonyango. Apho kwakukhe kwakho indlela enye, ngoku kukho iindlela ezininzi ezilungiselelwe izigaba ezahlukeneyo zesifo kunye neempawu zebhayoloji. Ukhetho lonyango luxhomekeke ngakumbi kunyango lwangaphambili, imeko yokusebenza, kunye neeprofayili ezithile ze-biomarker.

Ukulawula iZiphumo eziPhakamileyo kunye neeProfayili zoKhuseleko

Njengoko iinketho zonyango umhlaza wemiphunga encinci baba namandla ngakumbi, ukulawula iziphumo zabo ebezingalindelekanga kubaluleke ngokulinganayo. Udidi ngalunye lwechiza lubonisa inkangeleko yobutyhefu eyodwa efuna ulawulo olusebenzayo.

Iziganeko ezimbi eziNxulumene ne-Immunotherapy (irAEs)

I-immune checkpoint inhibitors inokubangela ukuvuvukala kuyo nayiphi na inkqubo yomzimba. Ii-IRAE eziqhelekileyo ziquka i-dermatitis, i-colitis, i-hepatitis, kunye ne-endocrinopathies ezifana nokungasebenzi kakuhle kwe-thyroid. Okubangel 'umdla kukuba, ezinye iinkcukacha zibonisa ukuba izigulana ezifumana i-IraEs ezinobuthathaka zinokuba neempendulo ezingcono ze-tumor, ezibonisa ukusebenza kokuqina komzimba.

Ulawulo lubandakanya i-corticosteroids kunye nokunqunyanyiswa okwethutyana kwechiza. Ukufunyaniswa kwangethuba kubalulekile. Izigulana zifundiswa ukuba zichaze iimpawu ezifana nokukhohlela okuzingileyo, urhudo, okanye ukudinwa ngoko nangoko. Ngokubeka iliso okufanelekileyo, uninzi lwe-IRAEs ziyabuyiswa kwaye ziyalawuleka.

I-ADC-Specific Toxicities

Ii-ADCs zizisa eyazo imingeni. Isifo se-Interstitial Lung (ILD) okanye i-pneumonitis ngumngcipheko owaziwayo kunye nomthwalo othile wentlawulo, ngakumbi ii-arhente ezisekelwe kwi-deruxtecan. Ukucinga rhoqo kunye novavanyo lomsebenzi we-pulmonary lugunyazisiweyo ngexesha lonyango. Ukongeza, iityhefu ze-hematologic ezifana ne-neutropenia kunye ne-thrombocytopenia zixhaphakile ngenxa yobume be-cytotoxic bomthwalo wokuhlawula.

I-nausea, ukudinwa, kunye ne-alopecia nazo zixhaphakile kodwa zilawuleka ngokubanzi ngononophelo lwenkxaso. Ifestile yonyango ye-ADCs imxinwa, ifuna i-dosing echanekileyo kunye nokuqwalaselwa okuphaphileyo liqela lezonyango.

Tarlatamab kunye noLawulo lweCRS

Ukusetyenziswa kwe-tarlatamab kufuna iiprothokholi ezikhethekileyo zokuphatha i-Cytokine Release Syndrome. Iimpawu zivela kwi-mild fever ukuya kwi-hypotension enzima kunye nokungasebenzi kakuhle kwamalungu. I-step-up dosing, apho iidosi zokuqala zisezantsi ukuze ngokuthe ngcembe ziqhelanise amajoni omzimba, kungqineke kusebenza ekwehliseni ubukhali be-CRS.

Ngaphaya koko, umngcipheko we-pneumonitis kunye ne-nephritis echongiweyo kuhlalutyo lwehlabathi lokwenyani kufuna ukuba oogqirha babeke iliso ngokusondeleyo ekusebenzeni kokuphefumla kunye nezintso. Nangona le mingcipheko, ukukwazi ukuxolelwa okuhlala ixesha elide kwiimeko eziphikisayo kwenza ezi zonyango zibe luncedo oluxabisekileyo kwi-toolkit ye-oncologist.

Amanyathelo asebenzayo kwizigulane kunye nabanonopheli

Ukuzulazula kwihlabathi elintsonkothileyo lonyango lwe-SCLC kunokuba nzima. Nasi isikhokelo esisebenzayo sokunceda izigulana kunye neentsapho zisebenzisana ngokufanelekileyo nababoneleli ngezempilo malunga iinketho zonyango umhlaza wemiphunga encinci.

• Inyathelo loku-1: qinisekisa iStaging kunye neSubtype: Qinisekisa ukuba i-staging echanekileyo (i-Limited vs. Ebanzi) isekwe nge-imaging ebanzi (CT, MRI, PET). Buza malunga ne-molecular subtyping ukuba ikhona, njengoko inokuchaphazela ukufaneleka kulingo lwezonyango.
• Inyathelo lesi-2: Xoxa ngeSicwangciso-qhinga sokuQala: Kwinqanaba elibanzi lesi sifo, qinisekisa ukuba isicwangciso sibandakanya ichemotherapy kunye ne-immune checkpoint inhibitor. Kwinqanaba elilinganiselweyo, buza malunga nexesha lokudibanisa i-immunotherapy emva kwe-chemoradiation.
• Inyathelo lesi-3: Phonononga iiMvavanyo zoNyango: Ukunika inguqu ekhawulezileyo yecandelo, buza ngokuthe ngqo malunga nolingo olubandakanya ii-ADCs okanye unyango olujoliswe kwi-DLL3. Uninzi lwezonyango ezinempumelelo zifikeleleka kuphela ngezi nkqubo.
• Inyathelo lesi-4: Isicwangciso sokubeka iliso: Ukuseka ishedyuli yokuskena rhoqo kunye nomsebenzi wegazi. Qonda imiqondiso yeziphumo ebezingalindelekanga ezifana ne-pneumonia okanye i-CRS kwaye wazi ixesha lokufuna unyango olungxamisekileyo.
• Inyathelo lesi-5: Qwalasela iNkathalo yeNkxaso: Dibanisa ukhathalelo lonyango kwangethuba. Oku akuthethi ukuba unikezele; kunokuba, igxile kulawulo lweempawu kunye nomgangatho wobomi, onokuthi ngokwenene ukwandisa ukusinda xa kudibaniswa nonyango olusebenzayo.

Ukuba ngummeli onolwazi kubalulekile. Imbonakalo yomhlaba ye iinketho zonyango umhlaza wemiphunga encinci itshintsha ngokukhawuleza kunanini na ngaphambili, kwaye ukuthatha inxaxheba ngokubonakalayo ekuthathweni kwezigqibo kunokukhokelela kwiziphumo ezingcono.

Izalathiso zexesha elizayo kunye neeHorizons zoPhando

Isantya kuphando lweSCLC alubonisi zimpawu zokucotha. Ngaphandle kolu nyango luphuhliswayo ngoku, iindlela ezininzi ezithembisayo ziyaphononongwa. Enye indawo enomdla kakhulu kukudityaniswa kwee-agent ezininzi zeenoveli, ezinjengokudibanisa i-DLL3-targeted BiTE kunye ne-ADC, okanye ukudibanisa i-immunomodulators ezintathu ezahlukeneyo.

Omnye umda kukusetyenziswa kobukrelekrele bokwenziwa ukuqikelela impendulo yonyango. Ngokuhlalutya iiseti zedatha enkulu ye-genomic kunye nolwazi lweklinikhi, iimodeli ze-AI zinokuthi ngokukhawuleza zikwazi ukucebisa eyona ilungileyo. iinketho zonyango umhlaza wemiphunga encinci kwizigulane ezichanekileyo ezichanekileyo.

Ngaphaya koko, ingqikelelo “yonyango olusebenzayo” iya isanda. Ngabasindi bexesha elide baye baxhaphake ngakumbi umbulelo kunyango lwe-immunotherapy kunye neearhente ezichongiweyo ezivelayo, injongo kukutshintsha ukusuka kulwandiso nje lobomi ukuya ekuzuzeni uxolelo olungenalunyango oluhlala luhleli. Uphando kwizicwangciso zolondolozo kunye neeprothokholi zokwehliswa kwabaphenduli bexesha elide ziyaqhubeka.

Izitofu zokugonya ezijolise kwii-antigens ezithile ze-SCLC nazo zikuphuhliso lwakwangoko. Ezi zitofu zokugonya zonyango zijolise ekuqeqesheni amajoni omzimba ukuba aqaphele kwaye atshabalalise iiseli zomhlaza ngokukhawuleza, ezinokuthi zithintele ukuphinda emva kwempumelelo yonyango lokuqala.

Isiphelo: Ukusa okutsha kwe-SCLC Care

Unyaka ka-2026 umi njengomzuzu wokuchitha ixesha kwimbali yomhlaza wemiphunga omncinci weseli. Utshintsho olusuka kumbono ongekho ngqiqweni ukuya kwelethemba lokwenyani luqhutywa bubungqongqo bezenzululwazi kunye nokucinga okutsha. Ukuhlanganiswa kwe-immunotherapy kumgangatho wokunyamekela kwakusisiqalo nje. Namhlanje, ukuvela kwe-antibody-drug conjugates efana nefinatamab deruxtecan kunye ne-iza-bren, ecaleni kokuchaneka konyango olujoliswe kwi-DLL3 njenge-tarlatamab, lunika amathuba angazange abonwe ngaphambili.

Izigulana ezifunyaniswe zine-SCLC namhlanje zinokufikelela kuluhlu olubanzi, oluntsonkothileyo lwe iinketho zonyango umhlaza wemiphunga encinci kunanini na ngaphambili. Ngelixa imiceli mngeni ihleli, ngakumbi ekulawuleni ubutyhefu kunye nokoyisa ukuxhathisa, umkhondo uphezulu ngokucacileyo. Intsebenziswano phakathi kwabaphandi, oogqirha, kunye nezigulana ziqhuba uguquko oluguqula uxilongo olubulalayo lube yimeko elawulekayo, kwaye ngamanye amaxesha iyanyangeka.

Njengoko sijonge kwikamva, ugxininiso luhlala kubuntu kunye nokuchaneka. Yonke into entsha efunyenweyo isisondeza kwinjongo yokugqibela: ukuphelisa umhlaza wemiphunga omncinci weseli. Okwangoku, umyalezo ucacile-kukho ithemba, kukho iinketho, kwaye umlo usesekude ukuba uphele.